Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06649864 · ClinicalTrials.gov registry record · Phase 1
Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications
A Phase 1 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06649864: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT06649864 is a Phase 1 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06649864, a Phase 1 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.
Interventions
- DRUG Autologous adipose derived mesenchymal stromal cells (AMSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2027-02 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06649864
The ClinicalTrials.gov registry entry for NCT06649864 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous adipose derived mesenchymal stromal cells (AMSC) is the first listed.
NCT06649864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06649864 about?
NCT06649864 is a clinical study titled "Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications". The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.
What is the current status of trial NCT06649864?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2027-02. Estimated completion is 2028-06.
What interventions are being tested in trial NCT06649864?
The interventions under investigation include: Autologous adipose derived mesenchymal stromal cells (AMSC) (DRUG).
Who is sponsoring clinical trial NCT06649864?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.